Blood Advances is a semimonthly medical journal published by the American Society of Hematology. It is the first journal to join the Blood family in 70 years and is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, Stanford University Medical Center, Stanford, CA, the inaugural issue debuted on November 29, 2016.
Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event
In this issue of Blood, Renga et al,1 in elegant experimental mouse models, compared the impact on gut microbiota, fungal colonization, and intestinal muco
In this issue of Blood, Murtadha et al demonstrate the efficacy of a new CD38-targeting immunotherapy for acute myeloid leukemia (AML).1
A single-chain CD38 T-cell engager targets CD38-negative LSCs activated by IFN-γ and induces CD38 expression on AML blasts.CD38 T-cell engager activates T
SLE occurs in 22% of children with ANA-associated AIC.Children of age >10 years and ANA titer >1/160 must be monitored long-term, for progression to
Although outcomes of various hematological diseases are improving, disparities continue to impact patients’ access to and outcomes following care. This
Blood Advances | 8 | 8 | April 2024
